Partner Randy D. Gordon, chair of the Firm’s antitrust and trade regulation practice, authored an article for Law360 regarding the antitrust issues associated with the Bayer-Monsanto deal.
“Bayer can make a credible case that it and Monsanto are not — for the most part — competitors in the two market dimensions that count in any antitrust analysis. First, with respect to product markets, Bayer has focused on herbicides in the agricultural space, whereas Monsanto has focused on seeds and genetic technology.”
Subscribers can access the full article here.
Related Insights
11 September 2024
Legal News: Employee Benefits Insights
Reminder: Qualified Professional Asset Managers (QPAM) Notice Deadline is September 15, 2024
Earlier this year, the Department of Labor updated the prohibited transaction exemption for Qualified Professional Asset Managers, often referred to as the “QPAM exemption.”
11 September 2024
Government Contractors Take Notice: Increase in Health & Welfare Fringe Benefit Rates Under the Service Contract Labor Standards
26 September 2024
Events
Billing/Coding/Legal & Regulatory Update
Foley partner Rachel Goodman is speaking in the Kentucky Rural Telehealth Summit in a session titled “Billing/Coding/Legal & Regulatory Update” on September 23.